Literature DB >> 33115867

Shared Mechanisms Govern HIV Transcriptional Suppression in Circulating CD103+ and Gut CD4+ T Cells.

Steven A Yukl1,2, Shahzada Khan3, Tsui-Hua Chen4,5, Martin Trapecar3, Frank Wu3, Guorui Xie3,6, Sushama Telwatte4,2, Daniel Fulop3, Alexander R Pico3, Gregory M Laird7, Kristen D Ritter7, Norman G Jones2, Chuanyi M Lu4,5, Robert F Siliciano8,9, Nadia R Roan3,6, Jeffrey M Milush2, Ma Somsouk10, Steven G Deeks2, Peter W Hunt2, Shomyseh Sanjabi11,12.   

Abstract

Latent HIV infection is the main barrier to cure, and most HIV-infected cells reside in the gut, where distinct but unknown mechanisms may promote viral latency. Transforming growth factor β (TGF-β), which induces the expression of CD103 on tissue-resident memory T cells, has been implicated in HIV latency. Using CD103 as a surrogate marker to identify cells that have undergone TGF-β signaling, we compared the HIV RNA/DNA contents and cellular transcriptomes of CD103+ and CD103- CD4 T cells from the blood and rectum of HIV-negative (HIV-) and antiretroviral therapy (ART)-suppressed HIV-positive (HIV+) individuals. Like gut CD4+ T cells, circulating CD103+ cells harbored more HIV DNA than did CD103- cells but transcribed less HIV RNA per provirus. Circulating CD103+ cells also shared a gene expression profile that is closer to that of gut CD4 T cells than to that of circulating CD103- cells, with significantly lower expression levels of ribosomal proteins and transcriptional and translational pathways associated with HIV expression but higher expression levels of a subset of genes implicated in suppressing HIV transcription. These findings suggest that blood CD103+ CD4 T cells can serve as a model to study the molecular mechanisms of HIV latency in the gut and reveal new cellular factors that may contribute to HIV latency.IMPORTANCE The ability of HIV to establish a reversibly silent, "latent" infection is widely regarded as the main barrier to curing HIV. Most HIV-infected cells reside in tissues such as the gut, but it is unclear what mechanisms maintain HIV latency in the blood or gut. We found that circulating CD103+ CD4+ T cells are enriched for HIV-infected cells in a latent-like state. Using RNA sequencing (RNA-seq), we found that CD103+ T cells share a cellular transcriptome that more closely resembles that of CD4+ T cells from the gut, suggesting that they are homing to or from the gut. We also identified the cellular genes whose expression distinguishes gut CD4+ or circulating CD103+ T cells from circulating CD103- T cells, including some genes that have been implicated in HIV expression. These genes may contribute to latent HIV infection in the gut and may serve as new targets for therapies aimed at curing HIV.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  CD103; CD4 T cell; HIV-1; PD-1; gamma delta T cell; human immunodeficiency virus; intestines; latency; tissue-resident memory cell; transforming growth factor receptors

Mesh:

Substances:

Year:  2020        PMID: 33115867      PMCID: PMC7944458          DOI: 10.1128/JVI.01331-20

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  79 in total

1.  The mTOR Complex Controls HIV Latency.

Authors:  Emilie Besnard; Shweta Hakre; Martin Kampmann; Hyung W Lim; Nina N Hosmane; Alyssa Martin; Michael C Bassik; Erik Verschueren; Emilie Battivelli; Jonathan Chan; J Peter Svensson; Andrea Gramatica; Ryan J Conrad; Melanie Ott; Warner C Greene; Nevan J Krogan; Robert F Siliciano; Jonathan S Weissman; Eric Verdin
Journal:  Cell Host Microbe       Date:  2016-12-14       Impact factor: 21.023

2.  Characterization of a human TAR RNA-binding protein that activates the HIV-1 LTR.

Authors:  A Gatignol; A Buckler-White; B Berkhout; K T Jeang
Journal:  Science       Date:  1991-03-29       Impact factor: 47.728

3.  HIV persistence in the gut mucosa of HIV-infected subjects undergoing antiretroviral therapy correlates with immune activation and increased levels of LPS.

Authors:  Gabriella d'Ettorre; Mirko Paiardini; Lorenzo Zaffiri; Mauro Andreotti; Giancarlo Ceccarelli; Cecilia Rizza; Marileda Indinnimeo; Stefano Vella; Claudio M Mastroianni; Guido Silvestri; Vincenzo Vullo
Journal:  Curr HIV Res       Date:  2011-04       Impact factor: 1.581

4.  Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy.

Authors:  Steven A Yukl; Amandeep K Shergill; Kenneth McQuaid; Sara Gianella; Harry Lampiris; C Bradley Hare; Mark Pandori; Elizabeth Sinclair; Huldrych F Günthard; Marek Fischer; Joseph K Wong; Diane V Havlir
Journal:  AIDS       Date:  2010-10-23       Impact factor: 4.177

5.  Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy.

Authors:  Tae-Wook Chun; David C Nickle; Jesse S Justement; Jennifer H Meyers; Gregg Roby; Claire W Hallahan; Shyam Kottilil; Susan Moir; Joann M Mican; James I Mullins; Douglas J Ward; Joseph A Kovacs; Peter J Mannon; Anthony S Fauci
Journal:  J Infect Dis       Date:  2008-03-01       Impact factor: 5.226

6.  CD4+ T Cells Expressing PD-1, TIGIT and LAG-3 Contribute to HIV Persistence during ART.

Authors:  Rémi Fromentin; Wendy Bakeman; Mariam B Lawani; Gabriela Khoury; Wendy Hartogensis; Sandrina DaFonseca; Marisela Killian; Lorrie Epling; Rebecca Hoh; Elizabeth Sinclair; Frederick M Hecht; Peter Bacchetti; Steven G Deeks; Sharon R Lewin; Rafick-Pierre Sékaly; Nicolas Chomont
Journal:  PLoS Pathog       Date:  2016-07-14       Impact factor: 6.823

7.  MultiQC: summarize analysis results for multiple tools and samples in a single report.

Authors:  Philip Ewels; Måns Magnusson; Sverker Lundin; Max Käller
Journal:  Bioinformatics       Date:  2016-06-16       Impact factor: 6.937

8.  PD-1 blockade potentiates HIV latency reversal ex vivo in CD4+ T cells from ART-suppressed individuals.

Authors:  Rémi Fromentin; Sandrina DaFonseca; Cecilia T Costiniuk; Mohamed El-Far; Francesco Andrea Procopio; Frederick M Hecht; Rebecca Hoh; Steven G Deeks; Daria J Hazuda; Sharon R Lewin; Jean-Pierre Routy; Rafick-Pierre Sékaly; Nicolas Chomont
Journal:  Nat Commun       Date:  2019-02-18       Impact factor: 14.919

9.  Entry of Polarized Effector Cells into Quiescence Forces HIV Latency.

Authors:  Curtis Dobrowolski; Saba Valadkhan; Amy C Graham; Meenakshi Shukla; Angela Ciuffi; Amalio Telenti; Jonathan Karn
Journal:  mBio       Date:  2019-03-26       Impact factor: 7.867

10.  VirusMINT: a viral protein interaction database.

Authors:  Andrew Chatr-aryamontri; Arnaud Ceol; Daniele Peluso; Aurelio Nardozza; Simona Panni; Francesca Sacco; Michele Tinti; Alex Smolyar; Luisa Castagnoli; Marc Vidal; Michael E Cusick; Gianni Cesareni
Journal:  Nucleic Acids Res       Date:  2008-10-30       Impact factor: 16.971

View more
  2 in total

1.  Common and Divergent Features of T Cells from Blood, Gut, and Genital Tract of Antiretroviral Therapy-Treated HIV+ Women.

Authors:  Guorui Xie; Sara Moron-Lopez; David A Siegel; Kailin Yin; Anastasia Polos; Jennifer Cohen; Ruth M Greenblatt; Phyllis C Tien; Sulggi A Lee; Steven A Yukl; Nadia R Roan
Journal:  J Immunol       Date:  2022-03-16       Impact factor: 5.422

2.  Tissue-specific differences in HIV DNA levels and mechanisms that govern HIV transcription in blood, gut, genital tract and liver in ART-treated women.

Authors:  Sara Moron-Lopez; Guorui Xie; Peggy Kim; David A Siegel; Sulggi Lee; Joseph K Wong; Jennifer C Price; Najwa Elnachef; Ruth M Greenblatt; Phyllis C Tien; Nadia R Roan; Steven A Yukl
Journal:  J Int AIDS Soc       Date:  2021-07       Impact factor: 5.396

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.